Drug results: 18
etofylline clofibrate | whole issue; structure given in first source | |
clofibric acid | An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. | |
clofibrate | A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) | |
aluminium clofibrate | ||
simfibrate | ||
etofibrate | analog of clofibrate with nicotinic acid substituted on the 2-carbon of the ethyl ester group; structure; RN given refers to parent cpd | |
binifibrate | two nicotinic & one clofibiric radical esterified by glycerol moiety | |
plafibride | morpholino-methylurea analog of clofibric acid | |
ronifibrate | ||
bezafibrate | An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS. | |
fenofibrate | An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood. | |
choline fenofibrate | metabolite of lipantyl; structure; salt of cholesterylamine & 2-(4-(p-chlorobenzoyl)phenoxy)2-methylpropionic acid | |
nicofibrate | ||
clinofibrate | ||
tocofibrate | ||
pemafibrate | Pemafibrate is a selective PPAR-alpha modulator (SPPARM-alpha) that has antihyperlipidaemic activity. | |
ciprofibrate | Ciprofibrate is a new derivative of phenoxyisobutyric acid which has a marked hypolipidaemic action. It reduces both LDL and VLDL and hence the levels of triglyceride and cholesterol associated with these lipoprotein fractions. It also increases levels of HDL cholesterol. | |
pirifibrate |
Citing DrugCentral © 2025. License